Tag: Powder

Posted on

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers.

Condition:   Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: Treatment A – AZD7594;   Drug: Treatment B – AZD7594;   Drug: Treatment C – AZD7594
Sponsor:   AstraZeneca
Not yet recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers.

Condition:   Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions:   Drug: Treatment A – AZD7594;   Drug: Treatment B – AZD7594;   Drug: Treatment C – AZD7594
Sponsor:   AstraZeneca
Not yet recruiting – verified October 2016

View full post on ClinicalTrials.gov: asthma | Studies received in the last 14 days

Posted on

Advancements in Devices and Particle Engineering in Dry Powder Inhalation Technology.

Related Articles

Advancements in Devices and Particle Engineering in Dry Powder Inhalation Technology.

Curr Top Med Chem. 2016 Feb 15;

Authors: Vadakkan MV, Vinod Kumar GS

Abstract
Dry powder inhalers (DPI) attracted the attention of pharmaceutical field due to its enlarging market share in inhalable formulations. These formulations also pose patient compliance and good shelf life. Earlier DPI formulations were intended for local effect in lung (asthma and chronic obstructive pulmonary diseases), whereas 21st century witnessed formulations intended for systemic effect too. A better understanding of physiology of lung and fluidics of air flow helped in targeting alveoli using DPI technology. Modern characterization tools also accelerated the research pace. In addition to the synthetic molecules, DPI also was proved to be a better system for delivering biological molecules including vaccines. This review includes the mechanisms of drug deposition, advancements in the fields of DPI devices, various characterization tools and particle engineering. In this review we have related the chronological advancement of inhalational technology starting from 1788 AD to the present.

PMID: 26876523 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Posted on

A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Fluticasone Furoate;   Drug: Vilanterol;   Drug: Fluticasone propionate;   Drug: Salmeterol;   Drug: Budesonide;   Drug: Formoterol Fumarate
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified May 2015

View full post on ClinicalTrials.gov: asthma | received in the last 14 days

Posted on

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Condition:   Asthma
Interventions:   Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler;   Drug: Placebo inhalation powders via ELLIPTA inhaler;   Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler;   Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler;   Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
Sponsor:   GlaxoSmithKline
Not yet recruiting – verified November 2014

View full post on ClinicalTrials.gov: asthma | received in the last 14 days